International Journal of Hematology

, Volume 92, Issue 2, pp 219–230

Pathogenesis of diffuse large B cell lymphoma

Progress in Hematology Molecular, cellular biology and treatment of B-cell lymphoma

DOI: 10.1007/s12185-010-0602-0

Cite this article as:
Chan, W.C. Int J Hematol (2010) 92: 219. doi:10.1007/s12185-010-0602-0


Substantial additional insight has been obtained in the past decade regarding the pathogenesis of diffuse large B cell lymphoma (DLBCL). Distinct subtypes of DLBCL have been defined by gene expression profiling (GEP) and they differ not only in GE profiles but also in the pattern of genetic abnormalities. The ability to correlate corresponding genetic and GEP data markedly facilitates the identification of target genes in regions with copy number abnormalities. Oncogenic pathways are often differentially activated in these different subtypes of DLBCL, suggesting that therapy should be targeted according to these differences. The tumor microenvironment plays a significant role in determining outcome and may be a novel target for therapy. The role of microRNA in lymphomagenesis is increasingly being recognized and mutation of key genes has been demonstrated to drive the activation of the NF-κB pathway and B cell receptor signaling. The pace of discovery will be even more rapid in the near future with the convergence of data from multiple complementary genome-wide studies and technological innovations including the rapid advance in the technology of high-throughput sequencing.


Diffuse large B-cell lymphomaPathogenesisOncogenic pathways

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  1. 1.Pathology and Microbiology and Center for Leukemia and Lymphoma ResearchUniversity of Nebraska Medical CenterOmahaUSA